Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.

PloS one | 2013

Cognitive impairments are prominent sequelae of prolonged continuous seizures (status epilepticus; SE) in humans and animal models. While often associated with dendritic injury, the underlying mechanisms remain elusive. The mammalian target of rapamycin complex 1 (mTORC1) pathway is hyperactivated following SE. This pathway modulates learning and memory and is associated with regulation of neuronal, dendritic, and glial properties. Thus, in the present study we tested the hypothesis that SE-induced mTORC1 hyperactivation is a candidate mechanism underlying cognitive deficits and dendritic pathology seen following SE. We examined the effects of rapamycin, an mTORC1 inhibitor, on the early hippocampal-dependent spatial learning and memory deficits associated with an episode of pilocarpine-induced SE. Rapamycin-treated SE rats performed significantly better than the vehicle-treated rats in two spatial memory tasks, the Morris water maze and the novel object recognition test. At the molecular level, we found that the SE-induced increase in mTORC1 signaling was localized in neurons and microglia. Rapamycin decreased the SE-induced mTOR activation and attenuated microgliosis which was mostly localized within the CA1 area. These findings paralleled a reversal of the SE-induced decreases in dendritic Map2 and ion channels levels as well as improved dendritic branching and spine density in area CA1 following rapamycin treatment. Taken together, these findings suggest that mTORC1 hyperactivity contributes to early hippocampal-dependent spatial learning and memory deficits and dendritic dysregulation associated with SE.

Pubmed ID: 23536771 RIS Download

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: F32 NS056664
  • Agency: NINDS NIH HHS, United States
    Id: T32 NS043124
  • Agency: NINDS NIH HHS, United States
    Id: F32 NS 56664
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS 39943
  • Agency: NINDS NIH HHS, United States
    Id: T32 NS 43124
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS49427

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions

SD (tool)

RRID:RGD_70508

Rattus norvegicus with name SD from RGD.

View all literature mentions

HCN1 ion channel (antibody)

RRID:AB_10672848

This monoclonal targets HCN1 ion channel

View all literature mentions

Kv1.4 potassium channel (antibody)

RRID:AB_10673576

This monoclonal targets Kv1.4 potassium channel

View all literature mentions

Anti-Kv1.2 K+ Channel Antibody (antibody)

RRID:AB_10674277

This monoclonal targets Kv1.2 potassium channel

View all literature mentions

Anti-Kv4.2 K+ Channel Antibody (antibody)

RRID:AB_2131945

This monoclonal targets Kv4.2 K+ channel

View all literature mentions

Anti-Kv1.4 K+ Channel Antibody (antibody)

RRID:AB_2249726

This monoclonal targets Kv1.4 K+ channel

View all literature mentions

Anti-HCN2 Antibody (antibody)

RRID:AB_2279449

This monoclonal targets HCN2

View all literature mentions

Anti-Kv1.2 K+ Channel Antibody (antibody)

RRID:AB_2296313

This monoclonal targets Kv1.2 K+ channel

View all literature mentions